Analyst Ratings for Arcutis Biotherapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Arcutis Biotherapeutics (NASDAQ:ARQT) in the last quarter, with 7 bullish and 3 somewhat bullish ratings. The average 12-month price target for the company is $43.8, a decrease of 11.34% from the previous average of $49.40.
June 28, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcutis Biotherapeutics has received positive ratings from analysts, but the average price target has decreased, indicating a potential decrease in stock price.
Analysts are generally bullish on ARQT, which could drive investor interest and potentially increase the stock price. However, the decrease in the average price target could indicate a less optimistic outlook, potentially leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100